Literature DB >> 30831628

[Outcomes of splenectomy in relapsed/refractory autoimmune hemolytic anemia].

S B Fan1, Z J Wang, Q Mao, C F Tong, W T Zhai, Y Z Zheng, C X Sun, J Shi.   

Abstract

Objective: To evaluate the outcomes of splenectomy in the treatment of relapsed/refractory autoimmune hemolytic anemia (AIHA).
Methods: Retrospective analysis was performed in 30 cases with relapsed/refractory AIHA who were treated with splenectomy in our hospital. The pre- and post-operative blood routine indexes and responses were followed up.
Results: Among the 30 relapsed/refractory AIHA patients, 20 were pure AIHA (including 13 patients with warm antibody AIHA, 2 with warm-cold double antibody AIHA and 5 with Coombs negative AIHA) and 10 were Evans syndrome. The short-term response was evaluated 10-14 days after operation, and the overall response rate (ORR) of short-term response was 90% [12 cases in complete response (CR), 6 cases in partial response (PR)] in 20 therapeutic evaluable cases. Among 13 patients with long-term follow-up data, except 3 patients with Evans syndrome died (2 cases were refractory to splenectomy, 1 case relapsed after surgery), the ORR of 10 patients with relapsed/refractory pure AIHA at 6 months and 12 months were 90% (9/10) and 70% (7/10), respectively, with a median follow-up of 14 (4-156) months. At the end of follow-up, 3 cases had maintained CR for more than 3 years.
Conclusion: The short-term response of splenectomy as a second-line treatment for relapsed/refractory AIHA is satisfactory, and long-term outcome of splenectomy is up to 70% at 1 year. Approximately one-third of patients could maintain sustained remission.

Entities:  

Keywords:  Autoimmune hemolytic anemia; Outcome; Refractory; Relapsed; Splenectomy

Mesh:

Substances:

Year:  2019        PMID: 30831628     DOI: 10.3760/cma.j.issn.0253-2727.2019.02.007

Source DB:  PubMed          Journal:  Zhonghua Xue Ye Xue Za Zhi        ISSN: 0253-2727


  1 in total

1.  [Ibrutinib treatment for 2 cases of relapsed/refractory autoimmune hemolytic anemia: a pilot study].

Authors:  L W Fang; H Pan; J Shi
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-05-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.